Teva Pharmaceutical Industries (TEVA) Net Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Net Margin came in at 13.91% in Q2 2026, down 2064.0% on a YoY basis from 0.71% in Q2 2025, and down 249.66% quarter-over-quarter from 9.29% in Q1 2026.
Powered by 
Analysis
Teva Pharmaceutical Industries (TEVA) Net Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported Net Margin for 18 consecutive years, with 13.91% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin fell 2064.0% year-over-year to 13.91%; the trailing twelve-month figure through Jun 2026 stood at 4.02% (up 511.0% YoY), and the FY2025 full-year result was 8.13%, up 1998.0% from the prior year.
- Net Margin fell to 13.91% in Q2 2026 per TEVA's latest filing, from 9.29% in the prior quarter.
- Across five years, Net Margin topped out at 13.59% in Q1 2024 and bottomed at 34.35% in Q4 2022.
- Historically, Net Margin has averaged 4.61% across 5 years, with a median of 2.57% in 2023.
- The sharpest annual moves came in 2022 and 2023: Net Margin plunged 3066 bps in 2022, then soared 4480 bps in 2023.
- Over 5 years, Net Margin stood at 34.35% in 2022, then surged by 130 bps to 10.46% in 2023, then sank by 191 bps to 9.48% in 2024, then surged by 205 bps to 9.98% in 2025, then slumped by 239 bps to 13.91% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 13.91%, 9.29%, and 9.98% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | -13.91% |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn | -3.16% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 5.50% |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn | 8.74% |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 9.12% |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | -121.81% |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 9.28% |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 16.50% |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn | 11.04% |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.91% |
| Mar 31, 2026 | 9.29% |
| Dec 31, 2025 | 9.98% |
| Sep 30, 2025 | 9.64% |
| Jun 30, 2025 | 6.73% |
| Mar 31, 2025 | 5.65% |
| Dec 31, 2024 | -9.48% |
| Sep 30, 2024 | -9.07% |
| Jun 30, 2024 | -21.04% |
| Mar 31, 2024 | 13.59% |
| Dec 31, 2023 | 10.46% |
| Sep 30, 2023 | 1.97% |
| Jun 30, 2023 | -23.39% |
| Mar 31, 2023 | -6.91% |
| Dec 31, 2022 | -34.35% |
| Sep 30, 2022 | 1.78% |
| Jun 30, 2022 | -7.34% |
| Mar 31, 2022 | -26.58% |
| Dec 31, 2021 | -3.68% |
| Sep 30, 2021 | 7.87% |